R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2021
Voltar para busca
Dado oficial do USPTO
KYMAB
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
29/04/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
22/05/2019
Data de registro
07/09/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/09/2021
Última transação
29/04/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Cambridge, GB
Examinador
MANGUBAT, ALEXANDER
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Kymab Limited
Representantes
Mark H. Tidman BAKER & HOSTETLER LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humanscancerinflammatoryautoimmune and infectious diseasesmedical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodiesfor medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseases and in the field of antibodies and immuno-oncology
Classe 42
Scientificmedical and technological servicesscientific researchanalysis and testing in the field of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncologyscientific researchanalysis and testing in the field of antibodies and cell repertoires and researchdevelopment and design in the field of sciencemedicinetechnology; industrial analysis and industrial research servicestestinganalysisevaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodiesimmuno-oncologyinflammationhaematology and infectious disease; Conducting clinical trials for others in the field of antibodiesmedical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discoveryclinical developmentantibodies and biological cells; chemical analysis; chemical research
Classe 44
Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnostics; Medical screening
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
01/08/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
21/04/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/03/2021
PUBO
PUBLISHED FOR OPPOSITION
23/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
17/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
17/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
17/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
17/02/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/10/2020
GNRT
NON-FINAL ACTION E-MAILED
09/10/2020
CNRT
NON-FINAL ACTION WRITTEN
09/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/08/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/08/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/08/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
16/03/2020
GNRT
NON-FINAL ACTION E-MAILED
16/03/2020
CNRT
NON-FINAL ACTION WRITTEN
16/03/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
09/03/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
21/02/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
21/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/02/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
14/02/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/02/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
14/02/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/01/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2019
GNRT
NON-FINAL ACTION E-MAILED
09/08/2019
CNRT
NON-FINAL ACTION WRITTEN
09/08/2019
DOCK
ASSIGNED TO EXAMINER
09/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2019
NWAP
NEW APPLICATION ENTERED
25/05/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KYMAB ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.